These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31398658)

  • 21. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Fonti GL; Chimenti MS; Greco E; Boffa L; Conigliaro P; Triggianese P; Perricone R
    Clin Exp Rheumatol; 2021; 39(1):223. PubMed ID: 32452349
    [No Abstract]   [Full Text] [Related]  

  • 22. Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Macaluso F; Guggino G; Ciccia F
    Clin Exp Rheumatol; 2021; 39(1):224. PubMed ID: 32452343
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis.
    Macaluso F; Guggino G; Mauro D; Rizzo C; Bignone R; Ciccia F
    Clin Exp Rheumatol; 2019; 37(6):1096. PubMed ID: 31287406
    [No Abstract]   [Full Text] [Related]  

  • 24. Secukinumab treatment for ankylosing spondylitis and concomitant Huntington's disease: real-world experience.
    Bulut Gökten D; Mercan R
    Clin Exp Rheumatol; 2024 Mar; 42(3):767. PubMed ID: 37877409
    [No Abstract]   [Full Text] [Related]  

  • 25. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK; Conaghan PG; Gossec L; Strand V; Østergaard M; Poddubnyy D; Williams N; Porter B; Shete A; Gilloteau I; Deodhar A
    Arthritis Care Res (Hoboken); 2022 May; 74(5):759-767. PubMed ID: 33227175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.
    Baraliakos X; Borah B; Braun J; Baeten D; Laurent D; Sieper J; Emery P; McInnes IB; van Laar JM; Wordsworth P; Wollenhaupt J; Kellner H; Colin L; Vandenhende F; Radford K; Hueber W
    Ann Rheum Dis; 2016 Feb; 75(2):408-12. PubMed ID: 26248638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J; Deodhar A; Marzo-Ortega H; Aelion JA; Blanco R; Jui-Cheng T; Andersson M; Porter B; Richards HB;
    Ann Rheum Dis; 2017 Mar; 76(3):571-592. PubMed ID: 27582421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
    Tseng JC; Wei JC; Deodhar A; Martin R; Porter B; McCreddin S; Talloczy Z
    Front Immunol; 2020; 11():561748. PubMed ID: 33324394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry.
    Karakaş A; Gulle S; Can G; Dalkılıc E; Akar S; Koca SS; Pehlivan Y; Senel S; Tufan A; Ozturk MA; Yilmaz S; Yazici A; Cefle A; Yüce İnel T; Erez Y; Sari I; Birlik M; Direskeneli H; Akkoc N; Onen F
    Mod Rheumatol; 2024 Mar; 34(3):584-591. PubMed ID: 37348053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generalized lichen sclerosus et atrophicus combined with ankylosing spondylitis responding to secukinumab.
    Ye Q; Chen KJ; Jia M; Deng LJ; Fang S
    Scand J Rheumatol; 2023 Mar; 52(2):217-218. PubMed ID: 36124779
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
    Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
    Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ixekizumab for the treatment of ankylosing spondylitis.
    Huang JX; Lee YH; Wei JC
    Expert Rev Clin Immunol; 2020 Aug; 16(8):745-750. PubMed ID: 32729361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of hidradenitis suppurativa with secukinumab in a patient with ankylosing spondylitis and Familial Mediterranean Fever.
    Unal Enginar A; Gundogdu M
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):19-21. PubMed ID: 34508267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unmet needs in the treatment of ankylosing spondylitis: a long-term observational study from a single university center.
    Pelechas E; Kaltsonoudis E; Voulgari PV; Drosos AA
    Rheumatol Int; 2019 Apr; 39(4):663-668. PubMed ID: 30877371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab.
    Himmler S; Branner JC; Ostwald DA
    J Comp Eff Res; 2021 Feb; 10(2):143-155. PubMed ID: 33252266
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of secukinumab in ankylosing spondylitis with tubercular uveitis.
    Mahendradas P; Jain VK; Thomas S; Kawali A; Sanjay S; Shetty BK
    Indian J Ophthalmol; 2020 Nov; 68(11):2569-2572. PubMed ID: 33120695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of secukinumab in the treatment of ankylosing spondylitis.
    Shah R; Perry L; Deodhar A
    Immunotherapy; 2015; 7(12):1241-7. PubMed ID: 26595091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
    Schett G; Baraliakos X; Van den Bosch F; Deodhar A; Østergaard M; Gupta AD; Mpofu S; Fox T; Winseck A; Porter B; Shete A; Gensler LS
    J Rheumatol; 2021 Aug; 48(8):1251-1258. PubMed ID: 33722947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
    Baraliakos X; Kivitz AJ; Deodhar AA; Braun J; Wei JC; Delicha EM; Talloczy Z; Porter B;
    Clin Exp Rheumatol; 2018; 36(1):50-55. PubMed ID: 28516874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.